Monday 21 August, 2017
Edition: English (US)
MMJ Observer
Tag Archives: NASDAQ:GWPH

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) happens to be a biopharmaceutical provider focusing on the discovery, development as well as the commercialization of a wide spectrum of therapeutics from its proprietary cannabinoid product platform. The...

By Jon Slotnick on Apr 19th, 2017
GW Pharmaceuticals

GW Pharmaceuticals Plc (NASDAQ:GWPH) has announced its bringing on board Scott Giacobello to serve in the capacity of the Chief Financial Officer. The company through its cannabinoid product platform has over the years engaged in the discovery,...

By Jaime Williams on Mar 9th, 2017
GW Pharmaceuticals

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) CEO Justin Gover will present at the upcoming Cowen and Company Annual Healthcare Conference on March 8, 2017. Several new drugs and therapies are being advanced at a rapidly increasing pace in the Cannabidiol...

By Emily Gibson on Mar 7th, 2017
GW Pharmaceuticals

Goldman Sachs initiated coverage on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) with a “Buy” rating and price target of $189. Four other groups lately updated their coverage. The target range as noted from the released reports is from $135...

By Emily Gibson on Jan 30th, 2017
GW Pharmaceuticals

GW Pharmaceuticals (NASDAQ:GWPH) may have started 2016 on the bumpy ride, but on the journey to this New Year, the road became pothole-free and 2017 entry remained more or less smoother. In the first week of January, as the company rode its...

By Emily Gibson on Jan 20th, 2017
GW Pharmaceuticals

The American Epilepsy Society’s 70th Annual Meeting was an important one for GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), as it sent off 2016 with its positive Epidiolex® (cannabidiol or CBD) Phase 3 data. The company said that the data it...